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Abstract
Introduction and Hypthosis—Missing data is frequently observed in clinical trials; high rates 
of missingness may jeopardize trial outcome validity.
Purpose—Describe rates of missing data over time, by type of data collected and to compare 
demographic and clinical factors associated with missingness among women who participated in 
two large randomized clinical trials of surgery for stress urinary incontinence, the Stress 
Incontinence Surgical Treatment Efficacy Trial (SISTEr) and the Trial of Midurethral Sling 
(TOMUS).
Methods—Proportions of participants that completed/missing each follow-up visit were 
calculated. Chi-square tests, Fisher’s exact tests and t tests were used to compare women with and 
without missing data, as well as the proportion of completeness for each component of the 
composite primary outcome.
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Results—Data completeness for the primary outcome computation differed by trial, nearly 
double in TOMUS (62.3%) compared to SISTEr (35.7%). The rates of completed follow-up in-
person visits decreased over time. A higher proportion of subjects attended all follow-up visits in 
the TOMUS trial and, overall, there was less missing data within the period that included 
collection of the primary outcome at 12 months. The highest proportion of completeness for the 
composite outcome variables was for the symptoms questionnaire (SISTEr: 100%, TOMUS: 
99.8%) and the urinary stress test (SISTEr: 96.1%, TOMUS: 96.7%). In both studies, the pad test 
was associated with the lowest proportion of complete data (SISTEr: 85.1%, TOMUS: 88.3%) and 
approximately 1 in ten participants had missing voiding diaries at the time of primary outcome 
assessment. Generally, in both trials, a higher proportion of younger participants had missing data.
This analysis lacks a patient perspective regarding the reason for missing data that could have 
provided additional information regarding participant burden, motivations for adherence and study 
design. In addition, we were unable to compare the effect of the differential primary outcome 
assessment time-point within an identically designed trial.
Conclusions—Missing visits and data increased with time. Questionnaire data and physical 
outcome data (urinary stress test) that could be assessed during an in-person visit were least prone 
to missing data, whereas variables that required participant effort while away from the research 
team (pad test, voiding diary) were more likely to be missing. Older participants were more likely 
to provide complete data.
Keywords
Missing data; Urinary Incontinence; Clinical Outcomes; Surgical Trials; Primary Outcome 
Measures
Introduction
High quality clinical trial outcomes are characterized by sound study design, consistent 
collection of complete information, and appropriate statistical analyses. Missing data in 
clinical trials has received increasing attention recently as it presents distinct challenges for 
data analysis and interpretation [1] [2]. Strategies to reduce missing data should be 
considered prior to trial initiation; ongoing monitoring of missing data during recruitment is 
also recommended to proactively reduce missing data [1]. Despite the common occurrence 
of missing data in clinical trials there have been few detailed reports on the factors that may 
influence missingness. Of particular interest is missing outcome data as study power may be 
diminished and statistical methods to address this problem are inadequate. This study aims 
to report the frequency of missing primary outcome data, the reasons why the data were not 
obtained, and study participant factors associated with missingness in two large randomized 
clinical trials of surgery for stress urinary incontinence, the Stress Incontinence Surgical 
Treatment Efficacy Trial (SISTEr), comparing outcomes from the Burch colposuspension to 
the pubovaginal sling and the Trial of Midurethral Sling (ToMUS) study which compared 
outcomes between the retropubic and transobturator midurethral sling approaches.
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The design and findings of SISTEr and TOMUS have been published previously [3–6]. All 
study participants provided written informed consent and the institutional review board at 
each participating site approved the study protocols. The primary outcome was assessed in 
SISTEr and TOMUS at 24 and 12 months respectively after surgery/randomization. The 
primary outcome for each trial was a composite measure which included the Medical, 
Epidemiologic and Social Aspects of Aging Project (MESA) questionnaire to quantify the 
self-reported components of stress incontinence [7,8], a self-completed 7 day voiding diary, 
urinary pad test and urinary stress test. The urinary pad test quantifies urine loss as measured 
by the weight of a perineal pad worn by the subjects during a standardized set of activities 
over a set period of time. We also collected data from the Incontinence Impact 
Questionnaire (IIQ) to evaluate the effect of incontinence on quality of life [7].
We assessed the proportion of women who completed each study visit and the reason for 
missing the visit data (i.e. missed visit, subject withdrawal from trial, refusal to provide data 
within an otherwise completed visit), as well as the pattern (timing) of missing data. If a 
woman was known to have met the definition of failure prior to the primary outcome visit, 
then her outcome data were complete for the time-to-event analysis even if she missed the 
primary outcome visit. A woman who did not meet the definition of failure prior to that visit 
and who did not attend the visit was censored at the last at which her outcome status was 
known. Retreatment was not a reason for withdrawal. Deaths were included in subjects lost 
to follow-up. Chi-square tests, Fisher’s exact tests and t tests were used to compare the two 
groups (no missing vs. missing), as appropriate. In addition, we assessed the proportion of 
completeness for each component of the composite primary outcome variable. Analysis was 
performed using SAS Version 9.3 (SAS Institute, Cary, NC). A 5% two-sided significance 
level was used for all statistical testing.
Results
Table 1 displays the rates of follow-up in-person visits completed and reasons for missing 
by visit, demonstrating that visit attended rates decreased over time. A higher proportion of 
subjects attended all follow-up visits in the TOMUS trial (Table 2) and, overall, there was 
less missing data within the period that included collection of the primary outcome at 12 
months.
At the time of primary outcome assessment, a similar proportion of participants completed 
their quality of life questionnaires (SISTEr: 95.5%, TOMUS: 97.8%). The highest 
proportion of completed data for the composite outcome variables was for the MESA 
questionnaire (SISTEr: 100%, TOMUS: 99.8%) and the urinary stress test (SISTEr: 96.1%, 
TOMUS: 96.7%). In both studies, the urinary pad test was associated with the lowest 
proportion of complete data (SISTEr: 85.1%, TOMUS: 88.3%) and approximately one in ten 
participants had missing voiding diaries (Table 3).
Table 4 displays the proportion of women who provided each component of the primary 
outcome at time of assessment. The proportion of women who provided all four components 
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was nearly twice as great in TOMUS (62.3%) compared to SISTEr: 35.7%), without major 
differences by surgical success status. A higher proportion of participants were censored 
prior to their primary outcome visit in SISTEr (20.6%) compared to TOMUS (6.0%).
In both trials, a higher proportion of younger participants had missing primary outcome data 
(Table 5). We also identified trial-specific associations; SISTEr participants with missing 
data were less likely to have had experienced adverse events and more likely to have had 
experienced surgical retreatment of stress urinary incontinence whereas TOMUS 
participants with missing data were more likely to have had fewer urinary incontinence 
episodes at baseline.
Discussion
The studies analyzed in this report experienced a relatively high rate of missing data 
involving the primary outcome composite measure. Our analysis quantified and 
corroborated the widely held belief that missing data increases over time. This finding may 
assist other clinical investigators in balancing the desire for long-term outcomes with the 
reality of missing data. Good clinical trial conduct places a high value on timely collection 
of all planned data, although a priority is typically placed on collection of primary outcome 
data.
It is possible that SISTEr follow-up was lower than in TOMUS due to the longer duration of 
follow-up in SISTEr, as it is harder to sustain follow-up compliance over a longer time 
period. Nevertheless even at the 12-month visit the SISTEr follow-up rate was slightly lower 
than the TOMUS rate. There is also likely an order effect, with the TOMUS trial following 
the SISTEr trial. The research teams are likely to have improved their skills in subject 
retention and their ability to improve data completeness.
Another reason for the differences between the two trials may be differences in eligibility 
criteria and morbidity of interventions. The SISTEr trial, which allowed concomitant 
abdominal surgery, was associated with a higher overall rate of adverse events compared to 
the subsequent TOMUS trial which did not allow concomitant abdominal surgery and used 
minimally invasive surgical techniques.
The use of composite outcome variables has advantages and disadvantages. Our findings 
that certain components of our composite outcome were more likely to be missing may 
inform other incontinence researchers regarding their choices to use these variables 
individually or within composite variables. Questionnaire data and physical finding data 
(urinary stress test) that could be assessed during a single visit were least prone to missing 
data, whereas variables that required participant activity while away from the research team 
(pad test, voiding diary) were more likely to be missing.
Our finding that younger participants were more likely to be associated with missing data 
adds weight to the need to include older participants in clinical research. Efforts to promote 
retention of younger subjects, while improving study adherence, may improve data 
completeness in this group. Older participants, in addition to broadening the generalizability 
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of research, appear to contribute complete data more reliably. This supports the national 
efforts to avoid ageism in research, especially for the elderly.
Despite the best efforts of the clinical research teams, missing data is likely to occur, 
requiring robust methods of analytic techniques to assess whether missingness is random. 
Our findings suggest that there may be demographic associations that require consideration 
to avoid unsound conclusions, including incorrect claims of treatment superiority that is due 
to differential drop-out. The National Academy encourages clinical trial investigators to 
consider proactive measures to reduce missing data in all participants, especially in these 
groups [1]. In addition to an on-going assessment of data quality, assessment of patterns of 
missingness may permit scientifically sound interventions that minimize missing data 
through the remainder of the trial.
The analytic approach to missing data is not uniform. Incomplete data can challenge the 
interpretation of trial outcomes, regardless of the analytic method used for missing data. 
Although we did not compare various analytic methods within these trials, the biostatistical 
literature is filled with cautionary guidance reminding investigators to assess whether 
missing data is occurring randomly or in patterns that may pose interpretation bias, limiting 
the impact of the trial itself.
Our analysis has several minor limitations, including a lack of patient perspective regarding 
the reason for missing data, which could have provided additional information regarding 
participant burden, motivation and study design. In addition, we were unable to compare the 
effect of the differential primary outcome assessment time-point within an identically 
designed trial, other surgical trials or other trials assessing other interventions, such as drugs, 
behavioral interventions or other incontinence treatments.
The findings from our analysis are strengthened by the high quality of trial designs, multi-
site participation, sufficient participant retention and quality control for data management by 
an experienced coordinating center. These results may be used to inform regarding types of 
data and how it is collected in future trials regarding urinary incontinence.
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Table 2
Pattern of missingness
SISTEr (n=655 randomized) TOMUS (n=597 randomized)
Primary outcome visit 24 months 12 months
Completed all FU visits 439 (67.0%) 523 (87.6%)
Completed primary outcome visit but missed 1 or more previous visits 71 (10.8%) 16 (2.7%)
Withdrew, refused or l.t.f.* prior to primary outcome visit 116 (17.7%) 48 (8.0%)
Missed primary outcome visit but not withdrawn, refused or l.t.f.* 29 (4.4%) 10 (1.7%)
*
lost to follow-up
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Table 3
Completeness of data among those who attended primary outcome visit
SISTEr (24 months) (N=510) TOMUS (12 months) (N=539)
IIQ completed 487 (95.5%) 527 (97.8%)
Measures for primary outcome completed
 MESA stress index 510 (100.0%) 538 (99.8%)
 Voiding diary 450 (88.2%) 490 (90.9%)
 Pad test 434 (85.1%) 476 (88.3%)
 Stress test 490 (96.1%) 521 (96.7%)
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Table 4
Completeness of primary outcome.
SISTEr (n=655 randomized) TOMUS (n=597 randomized)
Primary outcome visit: 24 months 12 months
Complete at primary outcome visit 234 (35.7%) 372 (62.3%)
 Success# 185 (79.1%)* 309 (83.1%)**
 Failure 49 (20.9%)* 63 (16.9%)**
Censored prior to primary outcome visit 135 (20.6%) 36 (6.0%)
Failed prior to primary outcome visit 286 (43.7%) 189 (31.7%)
#
Success/Failure Definitions were study specific:
For the SISTEr study, overall success was defined as no self-reported symptoms of urinary incontinence, an increase of less than 15 g in pad 
weight during a 24-hour pad test, no incontinence episodes recorded in a 3-day diary, a negative urinary stress test (no leakage noted on 
examination during cough and Valsalva maneuvers at a standardized bladder volume of 300 ml), and no retreatment for urinary incontinence 
(including behavioral, pharmacologic, and surgical therapies). The definition of success specific to stress incontinence was limited to no self-
reported symptoms of stress incontinence, a negative stress test, and no retreatment for stress incontinence.
The TOMUS study used a composite primary outcome, assessed at 12 months after randomization that included treatment success according to 
objective criteria and treatment success according to subjective criteria. The objective criteria were a negative provocative stress test, a negative 24-
hour pad test, and no retreatment (behavioral, pharmacologic, or surgical) for stress incontinence; the subjective criteria were the absence of self-
reported symptoms of stress-type urinary incontinence, as assessed with the use of the Medical, Epidemiological and Social Aspects of Aging 
questionnaire, no leakage recorded in a 3-day voiding diary, and no retreatment for stress incontinence.
*
N=234 was used for the denominator.
**
N=372 was used for the denominator.
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